Results 21 to 30 of about 8,158 (292)

NDRG1 Activity in Fat Depots Is Associated With Type 2 Diabetes and Impaired Incretin Profile in Patients With Morbid Obesity

Frontiers in Endocrinology, 2021
ObjectiveWe aimed to investigate insulin-, mTOR- and SGK1-dependent signaling basal states in morbidly obese patients’ fat. We analyzed the correlation between the signaling activity, carbohydrate metabolism, and incretin profiles of patients.MethodsThe ...
Iurii Stafeev, Igor Sklyanik, Elizaveta Mamontova, Elizaveta Mamontova, Elizaveta Mamontova, Svetlana Michurina, Svetlana Michurina, Svetlana Michurina, Ekaterina Shestakova, Kamil Yah’yaev, Anatoliy Yurasov, Anatoliy Yurasov, Denis Masnikov, Denis Masnikov, Maria Sineokaya, Elizaveta Ratner, Elizaveta Ratner, Alexander Vorotnikov, Mikhail Menshikov, Yelena Parfyonova, Yelena Parfyonova, Marina Shestakova   +21 more
doaj   +1 more source

Genetic variants affecting incretin sensitivity and incretin secretion [PDF]

Diabetologia, 2010
Recent genome-wide association studies identified several novel risk genes for type 2 diabetes. The majority of these type 2 diabetes risk variants confer impaired pancreatic beta cell function. Though the molecular mechanisms by which common genetic variation within these loci affects beta cell function are not completely understood, risk variants may
K, Müssig, H, Staiger, F, Machicao, H-U, Häring, A, Fritsche   +4 more
openaire   +2 more sources

Obesity without diabetes: the role of hormonal regulation

Терапевтический архив, 2020
Aim.Obese patients without diabetes present an interesting phenotype to explore protective mechanisms against type 2 diabetes (T2D) development. In our study we looked for specific hormonal features of obese patients without T2D. Materials and methods.
E. A. Shestakova, I. A. Sklyanik, A. S. Panevina, L. V. Nikankina, M. V. Shestakova, I. I. Dedov   +5 more
doaj   +1 more source

Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders

Frontiers in Pharmacology, 2022
GPR40 is a class A G-protein coupled receptor (GPCR) mainly expressed in pancreas, intestine, and brain. Its endogenous ligand is long-chain fatty acids, which activate GPR40 after meal ingestion to induce secretion of incretins in the gut, including GLP-
Hong-Ping Guan, Yusheng Xiong
doaj   +1 more source

Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies

Медицинский совет, 2020
The article discusses the potential opportunities for impact of antidiabetic drugs from the group of glucagon-like peptide-1 (GLP- 1) receptor agonists on the risks of development and progression of cardiovascular complications in patients with type 2 ...
Yu. Sh. Khalimov, V. G. Kuzmich
doaj   +1 more source

Incretin secretion and glucose metabolism in morbidly obese patients in the early and late periods after biliopancreatic diversion [PDF]

Терапевтический архив, 2016
Aim. To estimate the parameters of glucose metabolism and to assess the secretion of incretins in patients after biliopancreatic diversion (BPD) for morbid obesity (MO) in the early and late postoperative periods. Subjects and methods.
I I Dedov, G A Melnichenko, E A Troshina, E V Ershova, N V Mazurina, N A Ogneva, Yu I Yashkov, А V Ilyin   +7 more
doaj   +1 more source

Multicomponent Stapling of Glucagon‐Like Peptide‐1 Enables Receptor‐Guided PROTAC Delivery

Angewandte Chemie, EarlyView.
We report a stapled glucagon‐like peptide‐1 (GLP‐1) analogue created via multicomponent tryptophan‐mediated Petasis reaction (TMPR). This strategy yields a stabilised peptide with superior helicity and improved potency. Conjugation to a bromodomain‐containing protein 4 (BRD4) degrader creates the first GLP‐1‐guided targeted protein degrader (PROTAC ...
Jan L. Venne, Sona Krajcovicova, Graeme Davies, Hannah Bolt, Jefferson Revell, David R. Spring   +5 more
wiley   +2 more sources

orlistat improves release of gut hormones increasing satiety in obese women

Ожирение и метаболизм, 2014
Orlistat, which reduces fat absorption by inhibiting intestinal lipase is a registered drug for obesity pharmacotherapy. Meta-analyzes indicate various positive metabolic effects of orlistat, including improvements in glucose and lipid metabolism ...
Teona Albertovna Shvangiradze
doaj   +1 more source

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies [PDF]

Diabetes & Metabolism Journal
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as blockbuster drugs for treating metabolic diseases. Glucagon-like peptide-1 (GLP-1) plays a pivotal role in glucose homeostasis by enhancing insulin secretion, suppressing glucagon ...
Joon Seok Park, Kyu Sik Kim, Hyung Jin Choi   +2 more
doaj   +1 more source

Incretins, pregnancy, and gestational diabetes

, 2016
The number of pregnant women affected by gestational diabetes mellitus (GDM) is increasing among Caucasians, and East Asians. GDM also increases the risk for later advent of type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease in both ...
Nikolic D., Rizzo M., Al-Hashmi K., Busaidi N. A., Montalto G., Al-Dughaishi T., Banerjee Y., Rizvi A. A., Al-Rasadi K., Al-Waili K.   +9 more
core   +2 more sources